Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Formulation substitution: a frequently overlooked variable in cardiovascular drug management.

Reiffel JA.

Prog Cardiovasc Dis. 2004 Jul-Aug;47(1):3-10. Review. No abstract available.

PMID:
15517512
2.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Reiffel JA.

JAMA. 2009 Apr 22;301(16):1655; author reply 1655-6. doi: 10.1001/jama.2009.522. No abstract available.

PMID:
19383951
3.

Generic drugs revisited.

[No authors listed]

Med Lett Drugs Ther. 2009 Oct 19;51(1323):81-2. Review. No abstract available.

PMID:
19838144
4.

Are generic and brand name drugs different in terms of quality?

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2000 Feb;11(12):8. No abstract available.

PMID:
10732507
5.

[Comparative study of drug efficacy and drug additives between generic drugs and original drugs].

Katoh H, Yoshii M, Ozawa K.

Yakugaku Zasshi. 2007 Dec;127(12):2035-44. Japanese.

6.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Carter BL.

JAMA. 2009 Apr 22;301(16):1654; author reply 1655-6. doi: 10.1001/jama.2009.520. No abstract available.

PMID:
19383950
7.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Zema MJ.

JAMA. 2009 Apr 22;301(16):1654-5; author reply 1655-6. doi: 10.1001/jama.2009.521. No abstract available.

PMID:
19383949
8.

Generic medications: another variable in the treatment of illnesses.

Blier P.

J Psychopharmacol. 2007 Jul;21(5):459-60. No abstract available.

PMID:
17664245
9.

[Generics: essentially similar, bioequivalent but not identical].

Even-Adin D, De Muylder JA, Sternon J.

Rev Med Brux. 2001 Dec;22(6):513-20. Review. French.

PMID:
11811047
10.

Japanese guidance on bioavailability and bioequivalence.

Aoyagi N.

Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):28-31.

PMID:
11032086
11.
12.

Polymorphism in generic drug product development.

Snider DA, Addicks W, Owens W.

Adv Drug Deliv Rev. 2004 Feb 23;56(3):391-5. Review.

PMID:
14962588
13.

Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products.

Chang RK, Raw A, Lionberger R, Yu L.

AAPS J. 2013 Jan;15(1):41-52. doi: 10.1208/s12248-012-9411-0. Epub 2012 Oct 9. Review. Erratum in: AAPS J. 2015 Nov;17(6):1522.

14.

Considerations concerning generic formulations of immunosuppressive drugs.

Kahan BD.

Transplant Proc. 1999 May;31(3):1635-41. No abstract available.

PMID:
10331031
15.

Recommendations concerning the introduction of generic formulations of cyclosporine.

Kahan BD.

Transplant Proc. 1999 May;31(3):1634; discussion 1675-84. No abstract available.

PMID:
10331030
16.

Comment: Pharmacy and generic substitution of antiepileptic drugs: missing in action?

Hatton RC.

Ann Pharmacother. 2007 Sep;41(9):1550-1; author reply 1551-2. Epub 2007 Jul 24. No abstract available.

PMID:
17652128
17.

The importance of brand continuity in epilepsy drugs.

Goodwin M.

Nurs Times. 2005 Jun 21-27;101(25):26-7. Review.

PMID:
15997944
18.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
19.

Drug substitution in transplantation.

Huang M, Wimberley S.

Am J Kidney Dis. 1999 Jul;34(1):206. No abstract available.

PMID:
10428729
20.

Comment on Disintegration/dissolution profiles of copies of Fosamax (alendronate).

Bolaños Díaz R.

Curr Med Res Opin. 2004 Jul;20(7):1035-6; author reply 1036-7. No abstract available.

PMID:
15265248
Items per page

Supplemental Content

Write to the Help Desk